Abstract:Objective: The coronavirus disease (COVID-19) pandemic, resulting from human-to-human transmission of a novel severe acute respiratory syndrome coronavirus (SARS-CoV-2), has caused a global health emergency. The lack of a specific drug or treatment strategy against this disease makes it devastating. Given that the main protease (Mpro) of SARS-CoV-2 plays an indispensable role in viral polyprotein processing, its successful inhibition prevents viral replication and constrains virus spread. Therefore, developing an effective SARS-CoV-2 Mpro inhibitor to treat COVID-19 is imperative. Materials and methods: We employed a high-throughput screening (HTS) method based on fluorescence polarization (FP) assay and further confirmed by the fluorescence resonance energy transfer (FRET) method for the discovery of Mpro inhibitors. Then multiple approaches were taken to investigate the inhibition profiles of the hit compounds against Mpro, including 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) proliferation assay, surface plasmon resonance analysis (SPR), high-performance liquid chromatography-quadrupole-time-of-flight mass spectrometry (HPLC-Q-TOF-MS), cytopathic effect (CPE) assay, molecule docking, and the drug-likeness analysis. Results: In this study, four Mpro inhibitors with low toxicity were selected from HTS. According to SPR, all the hit compounds had medium binding affinities toward SARS-CoV-2 Mpro. HPLC-Q-TOF-MS results revealed the non-covalent linkage of each compound with SARS-CoV-2 Mpro. Molecule docking simulated the molecule interactions between each compound and the substrate binding pocket of SARS-CoV-2 Mpro. CPE assay was used to detect their inhibitory activities against coronaviruses HCoV-OC43 and HCoV-229E. In particular, the IMB63-8G compound demonstrated the highest antiviral potency [50% effective concentration (IC50) value of 1.71 μg/mL] and selectivity against HCoV-OC43 (SI = 39), which was more than 4-fold higher than that of ribavirin (RBV). Besides, the IMB63-8G compound possessed favorable drug-likeness characteristics. Conclusions: Our results will highlight the therapeutic potential of these compounds for the treatment of SARS-CoV-2 infection.

An ascidian Polycarpa aurata-derived pan-inhibitor against coronaviruses targeting Mpro

Structures of Two Coronavirus Main Proteases: Implications for Substrate Binding and Antiviral Drug Design.

Discovery of potential inhibitors targeting SARS-CoV-2 Mpro

Identification of potential natural inhibitors of SARS-CoV2 main protease by molecular docking and simulation studies

Acriflavine and proflavine hemisulfate as potential antivirals by targeting Mpro

Structural Basis of Main Proteases of MERS-CoV Bound to Antineoplastic Drug Carmofur

Structural Basis for the Inhibition of Coronaviral Main Proteases by a Benzothiazole-Based Inhibitor

Discovery of the covalent SARS‐CoV‐2 Mpro inhibitors from antiviral herbs via integrating target‐based high‐throughput screening and chemoproteomic approaches

Synthesis of SARS-CoV-2 Mpro inhibitors bearing a cinnamic ester warhead with in vitro activity against human coronaviruses

Structural basis for the inhibition of coronaviral main proteases by PF-00835231

Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases.

An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

Marine natural compounds as potents inhibitors against the main protease of SARS-CoV-2—a molecular dynamic study

Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study

Structural Basis of Main Proteases of Coronavirus Bound to Drug Candidate PF-07304814.

Bioguided Isolation of Cyclopenin Analogues as Potential SARS-CoV-2 Mpro Inhibitors from Penicillium citrinum TDPEF34

The Structure of the Porcine Deltacoronavirus Main Protease Reveals a Conserved Target for the Design of Antivirals.

Xanthohumol Is a Potent Pan-Inhibitor of Coronaviruses Targeting Main Protease

Structural Basis for Coronaviral Main Proteases Inhibition by the 3clpro Inhibitor GC376.

Discovery of new non-covalent and covalent inhibitors targeting SARS-CoV-2 papain-like protease and main protease